[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2008008397A2 - Mousse pharmaceutique à base d'acide gras - Google Patents

Mousse pharmaceutique à base d'acide gras Download PDF

Info

Publication number
WO2008008397A2
WO2008008397A2 PCT/US2007/015826 US2007015826W WO2008008397A2 WO 2008008397 A2 WO2008008397 A2 WO 2008008397A2 US 2007015826 W US2007015826 W US 2007015826W WO 2008008397 A2 WO2008008397 A2 WO 2008008397A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
acid
fatty acid
present
weight
Prior art date
Application number
PCT/US2007/015826
Other languages
English (en)
Other versions
WO2008008397A3 (fr
WO2008008397A8 (fr
Inventor
Albert Zorko Abram
Iulian Goldstein
Original Assignee
Stiefel Research Australia Pty Ltd
Stiefel Laboratories, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stiefel Research Australia Pty Ltd, Stiefel Laboratories, Inc. filed Critical Stiefel Research Australia Pty Ltd
Priority to CA2659095A priority Critical patent/CA2659095C/fr
Priority to ES07810355T priority patent/ES2393761T3/es
Priority to PL07810355T priority patent/PL2046121T3/pl
Priority to EP07810355A priority patent/EP2046121B1/fr
Priority to MX2009000507A priority patent/MX2009000507A/es
Publication of WO2008008397A2 publication Critical patent/WO2008008397A2/fr
Publication of WO2008008397A3 publication Critical patent/WO2008008397A3/fr
Publication of WO2008008397A8 publication Critical patent/WO2008008397A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams

Definitions

  • composition should also be cosmetically elegant and should not cause irritation, discomfort, or inconvenience.
  • Lotion and gel topical dosage forms have the disadvantage of extended rub-in, they may leave oily residues and are less suitable for application to large surface areas.
  • a solution dosage form readily runs off the site of application, and therefore it is difficult to apply controlled amounts of this type of dosage form.
  • the foamable compositions of the present invention break easily with shear and thus are suitable for the convenient topical delivery of a pharmaceutically active agent. These compositions may clearly be distinguished from traditional shaving cream foams which persist and require extended rub-in. Furthermore, the present compositions are cosmetically elegant, and are suitable for both application to large surface areas and targeted application to smaller areas.
  • the present invention provides a foamable composition, comprising: water and an organic solvent, wherein the organic solvent comprises a C 4 -C 30 fatty acid which is partially neutralized.
  • the foamable composition further comprises a pharmaceutically active agent.
  • the pharmaceutically active agent may be, for example, an immune response modifier compound, such as imiquimod.
  • the pharmaceutically active agent is present in an amount of from about 0.0001% to about 40% by weight, based on the total weight of the foamable composition.
  • the fatty acid is a C 4 -C 24 fatty acid, more preferably a C 8 -Ci 8 fatty acid, most preferably a C is fatty acid.
  • Ci 8 fatty acids include, but are not limited to, stearic acid, isostearic acid, oleic acid, vaccenic acid, linoleic acid, alpha- linolenic acid, gamma-linolenic acid and eleostearic acid.
  • the Cis fatty acid is isostearic acid or oleic acid.
  • the fatty acid is capric acid.
  • the present invention provides a foamable composition wherein the organic solvent is present in an amount of from about 10% to about 50% by weight, based on the total weight of the foamable composition.
  • the organic solvent comprising a fatty acid is neutralized up to about 50% with a base, more preferably from about 0.01% to about 40%, still more preferably from about 10% to about 40%, and most preferably from about 20% to about 40%, such as 20%, 25%, 30%, 35% or 40%.
  • the base can be, for example, an amine (e.g., triethanolamine), metal oxide, metal hydroxide, or the pharmaceutically active agent itself (in instances where the pharmaceutically active agent selected can act as a base), and mixtures thereof.
  • compositions further comprise a surfactant.
  • Suitable surfactants include, for example, a non ionic surfactant, a cationic surfactant, an anionic surfactant, a zwitterionic surfactant, an amphoteric surfactant or an ampho lytic surfactant, and mixtures thereof.
  • the surfactant is present in an amount up to about 50% by weight, based on the total weight of the foamable composition.
  • the surfactant is present in an amount of up to 10% by weight, based on the total weight of the composition.
  • water is present in an amount up to about 90% by weight, based on the total weight of the foamable composition (for example, from about 45 % to about 90 % by weight, based on the total weight of the foamable composition).
  • the compositions further comprise an emollient selected from the group consisting of an occlusive agent, an emollient oil, and a humectant.
  • the emollient can be an occlusive agent such as a mineral oil, grease, petrolatum, an animal fat, a vegetable fat, a water insoluble polymer, a fatty alcohol, and mixtures thereof.
  • the occlusive agent is present in an amount of about 0.1% to about 55% by weight, or about 0.1% to about 10% by weight, based on the total weight of the foamable composition.
  • compositions further comprise a buffering agent or a pH adjusting agent.
  • compositions further comprise at least one member selected from the group consisting of a viscosity reducer, a complexing agent, a gelling agent, an antioxidant, a thickener, a preservative, a corrosion inhibitor, a penetration enhancer, colors and fragrances.
  • the compositions further comprise an aerosol propellant selected from the group consisting of a hydrocarbon, a chlorofluorocarbon, dimethyl ether, hydrofluorocarbons, and mixtures thereof.
  • the propellant comprises a mixture of hydrocarbons.
  • the foamable composition is in a pressurized container.
  • the foamable composition is a foam when released from the pressurized container.
  • the foam breaks easily with shear.
  • the foam is homogenous.
  • the present invention provides imiquimod as the pharmaceutically active agent in an amount of about 0.001% to 10% by weight; a Ci 8 fatty acid as the organic solvent in an amount of from about 10% to about 50% by weight; a base in an amount from about 0.01% to about 30% by weight; and water in an amount of about 45% to about 90% by weight.
  • the present invention provides a method for treating a dermatological disorder in a mammal, comprising: administering a foamable composition as herein described to treat the dermatological disorder.
  • Figure 1 illustrates the results of the rheological characterization of several different foam types (according to the prior art).
  • foamable includes a composition that is capable of forming a foam.
  • pharmaceutically active agent refers to a substance having a pharmaceutical, pharmacological or therapeutic effect.
  • the pharmaceutically active agent may be in its free base or acid form, or in the form of salts, esters, solvates, or any other pharmaceutically acceptable derivatives, or as analogs, metabolites, pro-drugs, or components of molecular complexes.
  • immuno response modifier compound includes a compound which induces the production of one or more cytokines, e.g., Interferon ( ⁇ ), Tumor Necrosis Factor, and Interleukin-12, from hematopoietec cells including dendritic cells and/or monocyte/macrophages.
  • Immune response modifier compounds, immunosuppressant agents and immunomodulators include, among other options, cyclic peptides, such as cyclosporine, tacrolimus, tresperimus, pimecrolimus, sirolimus (rapamycin), verolimus, laflunimus, laquinimod and imidazoquinoline amines such as imiquimod.
  • cyclic peptides such as cyclosporine, tacrolimus, tresperimus, pimecrolimus, sirolimus (rapamycin), verolimus, laflunimus, laquinimod and imidazoquinoline amines such as imiquimod.
  • organic solvent includes water-miscible or -immiscible solvents capable of dissolving either or both of water-soluble and water- insoluble organic compounds.
  • water-miscible solvents useful in the present invention include, but are not limited to, short chained alcohols (e.g. ethanol and isopropanol), polyols (e.g. glycerol) and glycols (e.g. propylene glycol, polyethylene glycol, hexylene glycol, 1,3- butylene glycol and dipropylene glycol).
  • water-immiscible solvents useful in the present invention include, but are not limited to, an ester such as isopropyl myristate, C12-C15 alkyl benzoate, caprylic/capric glyceride or caprylic/capric triglyceride; a medium to long chain alcohol such as dodecanol or myristyl alcohol; an aromatic and/or alkyl pyrrolidone such as lauryl pyrrolidone; an aromatic and/or alkyl and/or cyclic ketone; an aromatic and/or alkyl and/or cyclic ether; substituted and/or unsubstituted aromatic; straight chain and/or branched chain and/or cyclic alkane or silicone.
  • an ester such as isopropyl myristate, C12-C15 alkyl benzoate, caprylic/capric glyceride or caprylic/capric triglyceride
  • a medium to long chain alcohol such
  • fatty acid includes a carboxylic acid having an aliphatic tail, typically from 4 to 30 carbon atoms long.
  • Fatty acids can be saturated, mono- unsaturated or poly-unsaturated.
  • Fatty acids can be straight chain or branched.
  • fatty acids useful in the present invention include, but are not limited to, butyric acid (C4), caproic acid (C6), caprylic acid (C8), capric acid (ClO), lauric acid (C12), myristic acid (C 14), palmitic acid (Cl 6), palmitoleic acid (C 16), stearic acid (C 18), isostearic acid (C 18), oleic acid (C18), vaccenic acid (C18), linoleic acid (C18), alpha-linolenic acid (C18), gamma-linolenic acid (C 18), arachidic acid (C20), gadoleic acid (C20), arachidonic acid (C20), eicosapentaenoic acid (C20), behenic acid (C22), erucic acid (C22), docosahexaenoic acid (C22), lignoceric acid (C24) and hexacosa
  • fatty acid derivative includes a fatty acid compound that has been modified by one or several chemical reactions, or a salt thereof.
  • carboxylic acid can be esterified, or converted to an amide.
  • carboxylic acid can be protected with a protecting group known to one of skill in the art, or reduced to an aldehyde or alcohol.
  • a protecting group known to one of skill in the art, or reduced to an aldehyde or alcohol.
  • amine includes ammonia, tri-alkyl amines such as triethyl amine, and ethanolamine. Other examples include tromethamine, dimethyl stearamine and PEG 15 cocamine. One of skill in the art will appreciate that other amines are useful in the present invention.
  • metal oxide includes the oxide of any alkaline earth metal such as Be, Mg, Ca, Sr and Ba.
  • Other useful metals include transition metals such as Sc, Ti, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, Y, Zr, Nb, Mo, Tc, Ru, Rh, Pd, Ag, Cd, La, Hf, Ta, W, Re, Os, Ir, Pt, Au, Hg and Ac, as well as post-transition metals such as Al, Ga, In, Tl, Ge, Sn, Pb, Sb, Bi, and Po.
  • Exemplary metal oxides include, but are not limited to, MgO and AI 2 O 3 .
  • metal hydroxide includes a compound of the formula (M n+ ) x (OH) xn , wherein the metal (M) can be any alkaline earth metal such as Be, Mg, Ca, Sr and Ba.
  • transition metals such as Sc, Ti, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, Y, Zr, Nb, Mo, Tc, Ru, Rh, Pd, Ag, Cd, La, Hf, Ta, W, Re, Os, Ir, Pt, Au, Hg and Ac, as well as post-transition metals such as Al, Ga, In, Tl, Ge, Sn, Pb, Sb, Bi, and Po.
  • Exemplary metal hydroxides include, but are not limited to, NaOH, KOH, Al(OH) 3 and
  • surfactant includes any agent that alters the surface properties of the oil and water components in the composition to aid in the formation of an emulsion.
  • Surfactants useful in the present invention include, but are not limited to, a non- ionic surfactant, a cationic surfactant, an anionic surfactant, a zwitterionic surfactant, an amphoteric surfactant, or an ampholytic surfactant, and mixtures thereof.
  • a surfactant's hydrophilic/lipophilic balance (HLB) describes the surfactant's affinity toward water or oil (1-20, with 1 being lipophilic and 20 being hydrophilic).
  • the HLB of a blend of two surfactants equals the weight fraction of surfactant A times its HLB value plus the weight fraction of surfactant B times its HLB value (weighted average).
  • the surface-active agent has a hydrophilic lipophilic balance (HLB) between about 9 and about 14, which is the required HLB (the HLB required to stabilize an o/w emulsion of a given oil) for most oils and hydrophobic solvents.
  • HLB hydrophilic lipophilic balance
  • non-ionic surfactants useful in the present invention include, but are not limited to, include fatty alcohols, fatty alcohol derivatives and fatty acid derivatives.
  • Anionic surfactants useful in the present invention include, but are not limited to, soaps including alkali soaps, such as sodium, potassium and ammonium salts of aliphatic carboxylic acids, usually fatty acids, such as sodium stearate. Additional anionic surfactants include organic amine soaps such as organic amine salts of aliphatic carboxylic acids, usually fatty acids, such as triethanolamine stearate. Cationic surfactants useful in the present invention include, but are not limited to, amine salts such as octadecyl ammonium chloride and quaternary ammonium compounds such as benzalkonium chloride. One of skill in the art will appreciate that other surfactants are useful in the present invention.
  • fatty alcohol includes an alcohol having an aliphatic tail, typically from 4 to 30 carbon atoms long.
  • Fatty alcohols can be saturated, mono-unsaturated, poly-unsaturated, linear or branched.
  • fatty alcohols useful in the present invention include, but are not limited to, lauryl alcohol (C 12), tetradecanol (C 14), pentadecanol (C15), cetyl alcohol (C16), stearyl alcohol (C18), oleyl alcohol (C18), eicosanol (C20) and behenyl alcohol (C22).
  • Fatty alcohols of the present invention are useful as an emollient, a bodying agent, a foam stabilizer and a surfactant, among others.
  • fatty alcohols are useful in the present invention.
  • fatty alcohol derivative includes a fatty alcohol compound that has been modified by one or several chemical reactions.
  • the alcohol can be oxidized to a carbonyl compound such as an aldehyde or carboxylic acid. Ln addition, the alcohol could be protected with a suitable protecting group known to one of skill in the art.
  • Other derivatives can include esters or ethers formed using a fatty alcohol.
  • sorbitan ester includes an ester of sorbitol and a fatty acid.
  • Sorbitan esters useful in the present invention include, but are not limited to, sorbitan monolaurate (Arlacel 20), sorbitan monopalmitate (Span-40), sorbitan monooleate (Span-80), sorbitan monostearate and sorbitan tristearate.
  • sorbitan monolaurate Allacel 20
  • Span-40 sorbitan monopalmitate
  • Span-80 sorbitan monooleate
  • sorbitan monostearate sorbitan tristearate.
  • sorbitan esters useful in the present invention include, but are not limited to, sorbitan monolaurate (Arlacel 20), sorbitan monopalmitate (Span-40), sorbitan monooleate (Span-80), sorbitan monostearate and sorbitan tristearate.
  • polyoxyethylene fatty alcohol ether includes an ether formed from a polyoxyethylene polymer chain and a fatty alcohol. Any of the fatty alcohols described above are useful as polyoxyethylene fatty alcohol ethers of the present invention. In addition, the polyoxyethylene segments can have from 5 to about 100 ethylene oxide units.
  • Polyoxyethylene fatty alcohol ethers useful in the present invention include, but are not limited to, polyoxyethylene (20) stearyl ether and polyoxyethylene (20) cetostearyl ether. One of skill in the art will appreciate that other polyoxyethylene fatty alcohol ethers are useful in the present invention.
  • the term "emollient” includes an agent that softens, soothes and improves the lipid content of the skin or other mucous membranes. Emollients accomplish this by either slowing water loss from the skin through the use of an occlusive agent, improving the lipid content of the skin with an emollient oil, or by increasing the amount of water in the skin by use of a humectant.
  • the occlusive agent in the foamable compositions of the present invention include, but are not limited to, a mineral oil, grease, petrolatum, an animal fat, a vegetable fat, a water insoluble polymer, a fatty alcohol, and mixtures thereof.
  • emollient oils include isostearic acid derivatives, isopropyl palmitate, lanolin oil, diisopropyl dimerate, diisopropyl adipate, dimethyl isosorbide, maleated soybean oil, octyl palmitate, isopropyl isostearate, cetyl lactate, cetyl ricinoleate, tocopheryl acetate, acetylated lanolin alcohol, cetyl acetate, phenyl trimethicone, glyceryl oleate, tocopheryl Hnoleate, wheat germ glycerides, arachidyl propionate, myristyl lactate, decyl oleate, propylene glycol ricinoleate, isopropyl lanolate, pentaerythrityl tetrastearate, neopentylglycol dicaprylate/dicaprate, hydrogenated coco-glycerides,
  • Humcctants are characterized as having several hydrophilic functional groups.
  • Humectants useful in the foamable compositions of the present invention include, but are not limited to, propylene glycol and polyols such as sorbitol, maltitol and polymeric polyols such as polydextrose.
  • propylene glycol and polyols such as sorbitol, maltitol and polymeric polyols such as polydextrose.
  • suitable emollients can be found in the Cosmetic Bench Reference, pp. 1.19-1.22 (1996).
  • One of skill in the art will appreciate that other emollients are useful in the present invention.
  • buffering agent includes any inorganic or organic acid or base that resists changes in pH and maintains the pH around a desired point.
  • Buffering agents useful in the present invention include, but are not limited to, sodium hydroxide, dibasic sodium phosphate anhydrous, and mixtures thereof.
  • buffering agents are useful in the present invention.
  • viscosity reducer includes an agent that reduces the viscosity of the composition.
  • Viscosity reducers useful in the foamable compositions of the present invention include, but are not limited to, isopropyl myristate, light mineral oil and cyclomethicone, and mixtures thereof.
  • isopropyl myristate include, but are not limited to, isopropyl myristate, light mineral oil and cyclomethicone, and mixtures thereof.
  • isopropyl myristate include, but are not limited to, isopropyl myristate, light mineral oil and cyclomethicone, and mixtures thereof.
  • One of skill in the art will appreciate that other viscosity reducers are useful in the present invention.
  • complexing agent includes an agent that is capable of complexing to other components of the composition.
  • Complexing agents useful in the foamable compositions of the present invention include, but are not limited to, edetate disodium dehydrate.
  • edetate disodium dehydrate One of skill in the art will appreciate that other complexing agents are useful in the present invention.
  • gelling agent includes an agent that is capable of increasing the viscosity of the composition.
  • Gelling agents can include, but are not limited to, natural gums, starches, pectins, sodium, potassium, ammonium, calcium, agar, carrageenan, locust bean gum and gelatin.
  • pectins sodium, potassium, ammonium, calcium, agar, carrageenan, locust bean gum and gelatin.
  • antioxidant includes an agent that prevents the oxidation of other compounds.
  • antioxidants useful in the compositions of the present invention include, but are not limited to, beta-carotene, selenium, coenzyme QlO
  • antioxidants include substances which, when added to a mixture, increase its viscosity without substantially modifying its other properties. Thickeners provide body, increase stability, and improve suspending action.
  • Thickeners useful in the compositions of the instant invention include, but are not limited to, agar, alginin, arrowroot, collagen, cornstarch, fecula, gelatin, guar gum, katakuri, locust bean gum, pectin, roux, tapioca, and xanthan gum.
  • thickeners are useful in the present invention.
  • aerosol propellant includes a gas that assists in propelling the foamable composition out of a pressurized container.
  • the aerosol propellant can be any suitable gas or mixture thereof, such as a hydrocarbon, a chlorofluorocarbon, dimethyl ether, hydrofluorocarbons, and mixtures thereof.
  • Hydrocarbon propellants include, but are not limited to, propane, /i-butane and isobutane. Chlorofluorocarbons are alkanes where the hydrogens have been replaced with chlorine and fluorine atoms.
  • Exemplary chlorofluorocarbons include, but are not limited to, chlorofluoromethanes such as trichlorofluoromethane and dichlorodifluoromethane, and chlorofluoroethanes such as trichlorotrifluoroethane.
  • Hydrofluorocarbons are alkanes where some hydrogens have been replaced with fluorine atoms, but some hydrogen atoms remain.
  • Exemplary hydrofluorocarbons include, but are not limited to, hydro fluoromethanes such as trifluoromethane, and hydrofluoroethanes such as tetrafluoroethane.
  • hydrofluorocarbons include, but are not limited to, hydro fluoromethanes such as trifluoromethane, and hydrofluoroethanes such as tetrafluoroethane.
  • the term “treat” or “treating” includes any indicia of success in the treatment or amelioration of an injury, pathology, condition, or symptom (e.g., pain), including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the symptom, injury, pathology or condition more tolerable to the patient; decreasing the frequency or duration of the symptom or condition; or, in some situations, preventing the onset of the symptom or condition.
  • the treatment or amelioration of symptoms can be based on any objective or subjective parameter; including, e.g., the result of a physical examination.
  • skin disorder includes an abnormal skin condition such as those described below.
  • foamable refers to the composition being able to form a foam. It can be worked into a foam, for example, following application to wet or dry skin. It can form a foam when dispensed from a device that allows air or vapor to be entrapped within the composition during dispensing, for example, an air aspirated foaming dispenser. It can form a foam when dispensed from an aerosol container, for example, wherein a liquefied propellant mixed with the composition facilitates the production of a foam.
  • the present invention provides a foamable composition comprising water and an organic solvent, wherein the organic solvent comprises a C4-C 30 fatty acid which is partially neutralized.
  • a pharmaceutically active agent may be incorporated in one or more phases of the foamable composition.
  • the most appropriate phase of incorporation will depend on the solubility characteristics of the pharmaceutically active agent and the desired release characteristics of the pharmaceutically active agent from the foamable composition.
  • Suitable pharmaceutically active agents include, but are not limited to, immune response modifier compounds, retinoids, vitamin D analogs, corticosteroids, antihistamines, antimicrobial agents, antifungal agents, antimalarial agents, antivirals, cytotoxic agents, psoralens, minoxidil, anti-androgens, antipruritic agents, keratolytic agents, tars, dithranol, antiseptics, sunscreens, anaesthetics and analgesics, and skin conditioning and nutritional agents, and mixtures thereof.
  • immune response modifier compounds include, but are not limited to, immune response modifier compounds, retinoids, vitamin D analogs, corticosteroids, antihistamines, antimicrobial agents, antifungal agents, antimalarial agents, antivirals, cytotoxic agents, psoralens, minoxidil, anti-androgens, antipruritic agents, keratolytic agents, tars, dithranol, antiseptics, sunscreens
  • Immune response modifier compounds, immunosuppressant agents, immunoregulating agents and immunomodulators are chemically or biologically-derived agents that modify the immune response or the functioning of the immune system (as by the stimulation of antibody formation or the inhibition of white blood cell activity).
  • Immune response modifier compounds, immunosuppressant agents and immunomodulators include, among other options, cyclic peptides, such as cyclosporine, tacrolimus, tresperimus, pimecrolimus, sirolimus (rapamycin), verolimus, lafhinimus, laquinimod and imidazoquinoline amines such as imiquimod, and mixtures thereof.
  • Additional compounds include imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, imidazonaphthpyridine amines, tetrahydroimidazonaphthpyridine amines, oxazolopyridine amines, oxazoloquinoline amines, thiazolopyridine amines, thiazoloquinoline amines and 1,2-bridged imidazoquinoline amines.
  • Such compounds and methods for preparing them are disclosed in, for example, U.S. Pat. Nos.
  • Preferred compounds include l-(2- methylpropyl)-lH-imidazo[4,5-c]quinolin-4-amine (imiquimod), 4-amino-2-ethoxymethyl- ⁇ , ⁇ -dimethyl-lH-imidazo[4,5-c]quinoline-l-ethanol (resiquimod), and 2- propyl[l,3]thiazolo[4,5-c]quinolin-4- amine.
  • R 1 , R 2 and R 3 are each independently selected from the group consisting of hydrogen, alkyl containing one to six carbon atoms and hydroxyalkyl containing one to six carbon atoms.
  • R 4 is an amine optionally substituted with an alkyl containing one to six carbon atoms and hydroxyalkyl containing one to six carbon atoms.
  • the compound is in a pharmaceutically acceptable salt form.
  • the immune response modifier compound is an imidazoquinoline amine. In another embodiment, the immune response modifier compound is imiquimod.
  • the immune response modifier compound is present in amounts from approximately 0.0001 % by weight to approximately 10% by weight, based on the total weight of the foamable composition. In other foamable compositions, the immune response modifier compound is present in amounts from approximately 0.001% to approximately 1% by weight. In still other foamable compositions, the immune response modifier compound is present in amounts from approximately 0.001% to approximately 0.1% by weight. In another foamable composition, the immune response modifier compound is present in amounts from approximately 0.001% to approximately 0.01% by weight.
  • foamable compositions having other amounts of the immune response modifier compound are useful in the present invention.
  • Exemplary retinoids include, but are not limited to, tretinoin, isotretinoin, etretinate, acitretin, adapalene and tarazotene, and mixtures thereof.
  • Exemplary vitamin D analogs include, but are not limited to, calcidiol, calcitriol, calcipotriene, paricalcitol, 22- oxacolcitriol, dihydrotachysterol, calciferol, and those listed in U.S. Pat. No. 6,787,529, and mixtures thereof.
  • corticosteroids useful in the present invention include, but are not limited to, alclometasone dipropionate, amcinonide, beclamethasone dipropionate, betamethasone benzoate, betamethasone dipropionate, betamethasone valerate, budesonide, clobetasol propionate, clobetasone butyrate, cortisone acetate, desonide, desoximetasone, diflorasone diacetate, diflucortolone valerate, fluclorolone acetonide, flumethasone pivalate, fluocinolone acetonide, fluocinonide, fluocortin butyl, fluocortolone preparations, fluprednidene acetate, flurandrenolide, flurandrenolone, fluticasone propionate, halcinonide, halobetasol propionate, hydrocortisone, hydrocortisone,
  • antihistamines include, but are not limited to, cetirizine, diphenhydramine, dimenhydrinate, perphenazine, triprolidine, pyrilamine, chlorcyclizine, promethazine, carbinoxamine, tripelennamine, brompheniramine, hydroxyzine, cyclizine, meclizine, clorprenaline, terfenadine, and chlorpheniramine, and mixtures thereof.
  • antimicrobial agents include, but are not limited to, amikacin, bacitracin, colistin, gentamicin, kanamycin, metronidazole, clindamycin, erythromycin, tetracycline, doxycycline, minocycline, dapsone, sulfapyridine, mupirocin, neomycin, netilmicin, polymyxin B, streptomycin, tobramycin, phenols and cresols such as 2,4-dichloro-sym- metaxylenol, parachlorometaxylenol, and parachlorometacresol, bisphenols such as hexachlorophene, dichlorophene, bithionol, triclosan, and fentichlor, salicylanilides such as 4',5-dibromsalicylanilide, 3',4',5-trichlorosalicylanilide, 3
  • Exemplary antifungal agents include, but are not limited to, those selected from the group consisting of imidazoles, hydroxy pyridones, triazoles, allyl amines, undecylenic acid derivatives, tolnaftate, haloprogin, pyridinethiones, cloquinol, amphotericin B, butoconazole nitrate, ciclopiroxolamine, clindamycin, clioquinol, clotrimazole, econazole, econazole nitrate, fluconazole, flucytosine, griseofulvin, itraconazole, ketoconazole, albaconazole, miconazole, micronazole, naftifine, nystatin, omadine disulfide, sulconazole, terbinafme, terconazole, tioconazole, tolnaftate, triacetin, unecylenic acid
  • antimalarial agents include, but are not limited to, 4-aminoquinolines, ⁇ c- aminoquinolines, chloroquine, hydroxychloroquine and pyrimethamine, and mixtures thereof.
  • Exemplary antivirals include, but are not limited to, aciclovir, carbovir, desciclovir, famciclovir, foscarnet sodium, ganciclovir sodium, interferons, penciclovir, valaciclovir hydrochloride, and mixtures thereof.
  • Exemplary cytotoxic agents include, but are not limited to, azathioprine, cyclophosphamide, cyclosporine, methotrexate, hydroxyurea, thalidomide, bleomycin and fluorouracil, and mixtures thereof.
  • An exemplary psoralen is methoxsalen.
  • Exemplary anti-androgens include, but are not limited to, spironolactone, cyproterone acetate, flutamide and finasteride, and mixtures thereof.
  • Exemplary antipruritics include, but are not limited to, calamine, camphor and menthol, and mixtures thereof.
  • Exemplary keratolytic agents include, but are not limited to, salicylic acid, benzoic acid, urea and propylene glycol, and mixtures thereof.
  • Exemplary tars include, but are not limited to, coal tar, pine tar and ichthammol, and mixtures thereof.
  • Exemplary antiseptics include, but are not limited to, benzoyl peroxide, hydrogen peroxide, chlorhexidine, cetrimide, povidone iodine and triclosan, and mixtures thereof.
  • Exemplary sunscreens include, but are not limited to, p-aminobenzoic acid and its derivatives (ethyl, isobutyl, glycerly esters), p-dimethylaminobenzoic acid and its derivitatives (ethyl, isobutyl, glyceryl esters), o-aminobenzoates and its derivatives (methyl, menthyl, phenyl, benzyl, phenylethyl, linaly, terpenyl, and cyclohexenyl esters), salicylates (amyl, phenyl, benzyl, menthyl, glyceryl, and dipropylene-glycol esters), cinnamic acid derivatives (menthyl and benzyl esters; alphphenyl cinnamonitrile; butly cinnamoyl pyruvate, 2-ethylhexyl p-methoxyc
  • anaesthetics and analgesics include, but are not limited to, benzocaine lidocaine, lignocaine, prilocaine and choline salicylate, and mixtures thereof.
  • Exemplary skin-conditioning agents include, but are not limited to, hydrocarbon oils and waxes, silicones, fatty acid derivatives, cholesterol, cholesterol derivatives, di- and triglycerides, vegetable oils, vegetable oil derivatives, liquid nondigestible oils such as those described in Mattson, U.S. Pat. No. 3,600,186 and Jandacek et al., U.S. Pat. Nos. 4,005,195 and 4,005,196, all of which are herein incorporated by reference in their entirety, or blends of liquid digestible or nondigestible oils with solid polyol polyesters such as those described in Jandacek, U.S. Pat. No. 4,797,300, and Letton, U.S. Pat. Nos.
  • the foamable compositions of the present invention comprise organic solvent, wherein the organic solvent comprises a C4-C 30 fatty acid which is partially neutralized.
  • fatty acid refers to a carboxylic acid having an aliphatic tail, typically from 4 to 30 carbon atoms long.
  • Fatty acids can be saturated, mono-unsaturated or poly-unsaturated.
  • Fatty acids can be straight chain or branched.
  • Branched fatty acids include iso-fatty acids that have a branch point at the penultimate carbon (one carbon from the chain end) as well as anteiso-fatty acids (one carbon from the penultimate carbon).
  • Fatty acids useful in the compositions of the present invention include, but are not limited to, butyric acid (C4), caproic acid (C6), caprylic acid (C8), capric acid (ClO), lauric acid (Cl 2), myristic acid (C14), palmitic acid (C16), palmitoleic acid (C16), stearic acid
  • C 18 isostearic acid (C 18), oleic acid (Cl 8), vaccenic acid (C 18), linoleic acid (C 18), alpha- linolenic acid (C 18), gamma-linolenic acid (C 18), eleostearic acid (C 18), arachidic acid (C20), gadoleic acid (C20), arachidonic acid (C20), eicosapentaenoic acid (C20), behenic acid (C22), erucic acid (C22), docosahexaenoic acid (C22), lignoceric acid (C24) and hexacosanoic acid (C26).
  • Preferred fatty acids are C 4 -C 24 fatty acids. More preferred fatty acids are C 8 -C is fatty acids. Most preferred fatty acids are Ci 8 fatty acids. Preferred Ci 8 fatty acids useful in the present invention are stearic acid, isostearic acid, oleic acid, vaccenic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid and eleostearic acid. In still other embodiments, the fatty acid is an iso-fatty acid such as iso-stearic acid. In other embodiments, the fatty acid is capric acid. The organic solvents of the present invention are present in an amount of from about 10% to about 50% w/w, based on the total weight of the foamable composition. One of skill in the art will appreciate that other fatty acids and their derivatives are useful in the present invention.
  • the foamable compositions of the present invention may comprise organic solvent in addition to the C4-C 30 fatty acid.
  • This additional organic solvent may be water-miscible or water-immiscible.
  • a water-miscible solvent may, for example, act as a humectant, a penetration enhancer, or as a cosolvent to effect dissolution of the pharmaceutically active agent into the water phase.
  • the water-immiscible solvent may, for example, act as an emollient, a penetration enhancer, or as a cosolvent to effect dissolution of the pharmaceutically active agent into the fatty acid based oil phase.
  • water-miscible solvents useful in the present invention include, but are not limited to, short chained alcohols (e.g.
  • ethanol and isopropanol examples include polyols (e.g. glycerol) and glycols (e.g. propylene glycol, polyethylene glycol, hexylene glycol, 1,3-buytlene glycol and dipropylene glycol).
  • polyols e.g. glycerol
  • glycols e.g. propylene glycol, polyethylene glycol, hexylene glycol, 1,3-buytlene glycol and dipropylene glycol.
  • water-immiscible solvents useful in the present invention include, but are not limited to, esters such as isopropyl myristate, Ci 2 -CiS alkyl benzoate, caprylic/capric glyceride or caprylic/capric triglyceride; a medium to long chain alcohol for example dodecanol or myristyl alcohol; an aromatic and/or alkyl pyrrolidone such as lauryl pyrrolidone; an aromatic and/or alkyl and/or cyclic ketone; an aromatic and/or alkyl and/or cyclic ether; substituted and/or unsubstituted aromatic; straight chain and/or branched chain and/or cyclic alkane or silicone.
  • esters such as isopropyl myristate, Ci 2 -CiS alkyl benzoate, caprylic/capric glyceride or caprylic/capric triglyceride
  • the fatty acid organic solvents of the present invention are partially neutralized by the addition of a base.
  • the fatty acid organic solvent is neutralized up to 50% with a base.
  • the fatty acid organic solvent is neutralized from about 20% to about 40% with a base. It is thought that the partially neutralized fatty acid acts as an in situ surfactant, thus emulsifying the un-neutralized fatty acid within the water phase. This, in turn, permits the pharmaceutically active agent to be incorporated into one or more phases of the composition, including the water phase, the dispersed fatty acid based oil phase and the surfactant micelles.
  • the base used to neutralize the fatty acid organic solvent can be an amine, a metal oxide, a metal hydroxide or the pharmaceutically active agent (in instances where the pharmaceutically active agent selected can act as a base), and mixtures thereof.
  • Amines useful as a base in the present invention include, but are not limited to, ammonia, tri-alkyl amines such as triethyl amine, and ethanolamine.
  • the metal part of the metal oxide and metal hydroxide bases can be any alkaline earth metal such as Be, Mg, Ca, Sr and Ba.
  • transition metals such as Sc, Ti, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, Y, Zr, Nb, Mo, Tc, Ru, Rh, Pd, Ag, Cd, La, Hf, Ta, W, Re, Os, Ir, Pt, Au, Hg and Ac, as well as post-transition metals such as Al, Ga, In, Tl, Ge, Sn, Pb, Sb, Bi, and Po.
  • Exemplary metal oxides include, but are not limited to, MgO and Al 2 O 3 .
  • Exemplary metal hydroxides include, but are not limited to, CsOH, KOH, NaOH and Al(OH) 3 .
  • the solvent of the present invention may comprise a mixture of two or more of the above organic solvents in any proportion.
  • One of skill in the art will appreciate that other organic solvents are useful in the present invention.
  • the foamable compositions of the present invention can also comprise a surfactant, in addition to the surfactant generated in situ by the partial neutralization of the fatty acid.
  • Surfactants useful in the present invention include, but are not limited to, a non-ionic surfactant, a cationic surfactant, an anionic surfactant, a zwitterionic surfactant, an amphoteric surfactant, or an ampholytic surfactant, and mixtures thereof.
  • Surfactants include any agent that alters the surface properties of the oil and water components in the composition to aid in the formation of an emulsion.
  • a surfactant's hydrophilic/lipophilic balance (HLB) describes the surfactant's affinity toward water or oil.
  • the HLB scale ranges from 1 (totally lipophilic) to 20 (totally hydrophilic), with 10 representing an equal balance of both characteristics.
  • Lipophilic surfactants tend to form water-in-oil (w/o) emulsions; hydrophilic surfactants tend to form oil-in- water (o/w) emulsions.
  • the HLB of a blend of two surfactants equals the weight fraction of surfactant A times its HLB value plus the weight fraction of surfactant B times its HLB value (weighted average).
  • the surface-active agent has a hydrophilic lipophilic balance (HLB) between about 9 and about 14, which is the required HLB (the HLB required to stabilize an o/w emulsion of a given oil) of most oils and hydrophobic solvents.
  • HLB hydrophilic lipophilic balance
  • the composition has a single surface active agent having an HLB value between about 9 and 14, and in one or more embodiments, the foam composition contains more than one surface active agent and the weighted average of their HLB values is between about 9 and about 14.
  • Non-ionic surfactants useful in the present invention include, but are not limited to, fatty alcohols, fatty alcohol derivatives and fatty acid derivatives.
  • Fatty alcohols useful as surfactants in the present invention include, but are not limited to, lauryl alcohol (Cl 2), tetradecanol (C 14), pentadecanol (C 15), cetyl alcohol (C 16), stearyl alcohol (Cl 8), oleyl alcohol (C 18), eicosanol (C20) and behenyl alcohol (C22).
  • Fatty alcohol derivatives useful as non- ionic surfactants also include, but are not limited to, ethers of polyethylene glycol and fatty alcohols such as PEG-3 oleyl ether (Volpo 3) and PEG-4 lauryl ether (Brij 30).
  • PEG-ethers include ceteareth-20, formed from cetearyl alcohol and PEG-20. Cetearyl alcohol is a mixture of cetyl alcohol and stearyl alcohol.
  • Fatty acid derivatives useful as non-ionic surfactants include, but are not limited to, glycerol fatty acid esters such as glycerol monostearate, glycol fatty acid esters such as propylene glycol monostearate, polyhydric alcohol fatty acid esters such as polyethylene glycol (400) monooleate, polyoxyethylene fatty acid esters such as polyoxyethylene (40) stearate, polyoxyethylene fatty alcohol ethers such as polyoxyethylene (20) stearyl ether and polyoxyethylene (20) cetostearyl ether, polyoxyethylene sorbitan fatty acid esters such as polyoxyethylene sorbitan monostearate, sorbitan esters such as sorbitan monolaurate (Arlacel 20), sorbitan monopalmitate (Span-40), sorbitan monooleate (Span-80), sorbitan monostearate and sorbitan tristearate, alkyl glycosides such as cetearyl glucoside,
  • non-ionic surfactants include polyethoxylated fatty acids, fatty acid diesters, polyethylene glycol glycerol fatty acid esters, alcohol-oil transesterification products, polyglycerized fatty acids, sterol and sterol derivatives, polyethylene glycol sorbitan fatty acid esters, polyethylene glycol alkyl ethers, sugar esters, polyethylene glycol alkyl phenols, polyoxyethylene-polyoxypropylene block copolymers, sorbitan fatty acid esters and lower alcohol fatty acid esters.
  • Additional surfactants useful in the present invention include polysorbates, such as polyoxyethylene (20) sorbitan monostearate (T ween 60) and poly (oxyethylene) (20) sorbitan monooleate (Tween 80); poly (oxyethylene) (POE) fatty acid esters, such as Myrj 45, Myrj 49 and Myrj 59; poly (oxyethylene) alkylyl ethers, such as poly (oxyethylene) cetyl ether, poly (oxyethylene) palmityl ether, polyethylene oxide hexadecyl ether, polyethylene glycol cetyl ether, brij 38, brij 52, brij 56 and brij Wl; sucrose esters, partial esters of sorbitol and its anhydrides, such as sorbitan monolaurate and sorbitan monolaurate; mono or diglycerides and isoceteth-20.
  • polysorbates such as polyoxyethylene (20) sorbitan monostearate (T ween 60) and poly
  • Additional surfactants include PEG-fatty acid esters.
  • Exemplary monoesters include esters of lauric acid, oleic acid, and stearic acid, e.g., PEG-8 laurate, PEG-8 oleate, PEG-8 stearate, PEG-9 oleate, PEG-10 laurate, PEG-IO oleate, PEG- 12 laurate, PEG- 12 oleate, PEG- 15 oleate, PEG-20 laurate and PEG-20 oleate.
  • Polyethylene glycol fatty acid diesters suitable for use as non-ionic surfactants in the compositions of the present invention include PEG-20 dilaurate, PEG-20 dioleate, PEG-20 distearate, PEG-32 dilaurate and PEG- 32 dioleate.
  • Suitable polyethylene glycol glycerol fatty acid esters include PEG-20 glyceryl laurate, PEG-30 glyceryl laurate, PEG-40 glyceryl laurate, PEG-20 glyceryloleate, and PEG- 30 glyceryl oleate.
  • a large number of surfactants of different degrees of hydrophobicity or hydrophilicity can be prepared by reaction of alcohols or polyalcohols with a variety of natural and/or hydrogenated oils.
  • the oils used are castor oil or hydrogenated castor oil, or an edible vegetable oil such as corn oil, olive oil, peanut oil, palm kernel oil, apricot kernel oil, or almond oil.
  • Preferred alcohols include glycerol, propylene glycol, ethylene glycol, polyethylene glycol, sorbitol, and pentaerythritol.
  • preferred hydrophilic surfactants are PEG-35 castor oil (Incrocas-35), PEG-40 hydrogenated castor oil (Cremophor RH 40), PEG-25 trioleate
  • TGAT® TO PEG-60 com glycerides
  • Crovol M70 PEG-60 almond oil
  • Crovol A70 PEG-40 palm kernel oil
  • Crovol PK70 PEG-50 castor oil
  • Emalex C-50 PEG-50 hydrogenated castor oil
  • Emalex HC-50 PEG-8 caprylic/capric glycerides
  • Nebrasol PEG-8 caprylic/capric glycerides
  • Softigen 767 PEG-6 caprylic/capric glycerides
  • Preferred hydrophobic surfactants in this class include PEG-5 hydrogenated castor oil, PEG-7 hydrogenated castor oil, PEG-9 hydrogenated castor oil, PEG-6 corn oil (Labrafil® M 2125 CS), PEG-6 almond oil (Labrafil® M 1966 CS), PEG-6 apricot kernel oil (Labrafil® M 1944 CS), PEG-6 olive oil (Labrafil® M 1980 CS), PEG-6 peanut oil (Labrafil® M 1969 CS), PEG-6 hydrogenated palm kernel oil (Labrafil® M 2130 BS), PEG-6 palm kernel oil (Labrafil® M 2130 CS), PEG-6 triolein (Labrafil® b M 2735 CS), PEG-8 corn oil (Labrafil® WL 2609 BS), PEG-20 corn glycerides (Crovol M40), and PEG-20 almond glycerides (Crovol A40).
  • the latter two surfactants are reported to have HLB values of 10, which is generally considered to be the approximate border line between
  • Alcohol-oil transesterif ⁇ cation derivatives of oil soluble vitamins e.g., vitamins A, D, E, K, etc.
  • oil soluble vitamins e.g., vitamins A, D, E, K, etc.
  • TPGS tocopheryl PEG-100 succinate
  • Polyglycerol esters of fatty acids are also suitable non-ionic surfactants for the present invention.
  • exemplary use hydrophobic surfactants include polyglyceryl oleate (Plurol Oleique), polyglyceryl-2 dioleate (Nikkol DGDO), and polyglyceryl- 10 trioleate.
  • Preferred hydrophilic surfactants include polyglyceryl- 10 laurate (Nikkol Decaglyn 1-L), polyglyceryl-10 oleate (Nikkol Decaglyn 1- O), and polyglyceryl-10 mono, dioleate (Caprol® PEG 860).
  • Polyglyceryl polyricinoleates Polymuls are hydrophilic and hydrophobic surfactants of this class.
  • Sterols and derivatives of sterols are suitable surfactants for use in the present invention. These surfactants can be hydrophilic or hydrophobic. Preferred derivatives include the polyethylene glycol derivatives. An exemplary hydrophobic surfactant in this class is cholesterol. An exemplary hydrophilic surfactant in this class is PEG-24 cholesterol ether (Solulan C-24).
  • PEG-sorbitan fatty acid esters are suitable for use as non-ionic surfactants in the present invention.
  • these surfactants are hydrophilic, although several hydrophobic surfactants of this class can be used.
  • exemplary hydrophilic surfactants include PEG-20 sorbitan monolaurate (Tween-20), PEG-20 sorbitan monopalmitate (Tween-40), PEG-20 sorbitan monostearate (Tween-60), and PEG-20 sorbitan monooleate (Tween-80).
  • the polyoxyethylene-polyoxypropylene (POE-POP) block copolymers are a unique class of polymeric surfactants.
  • the unique structure of the surfactants, with hydrophilic POE and hydrophobic POP moieties in well-defined ratios and positions, provides a wide variety of surfactants suitable for use in the present invention.
  • These surfactants are available under various trade names, including Synperonic PE series (ICI), Pluronic® series (BASF), Emkalyx, Lutrol (BASF), Supronic, Monolan, Pluracare, and Plurodac.
  • the generic term for these polymers is "poloxamer” (CAS 9003-1 1-6).
  • Exemplary hydrophilic surfactants of this class include Poloxamers 108,188, 217,238, 288,338, and 407.
  • Exemplary hydrophobic surfactants in this class include Poloxamers 124,182, 183,212, 331, and 335.
  • the surface-active agent comprise mono-, di- and tri-esters of sucrose with food fatty acids (sucrose esters), prepared from sucrose and methyl and ethyl esters of food fatty acids or by extraction from sucroglycerides.
  • sucrose esters include sucrose monopalmitate and sucrose monolaurate.
  • Suitable sucrose esters include those having a high monoester content, which have higher HLB values.
  • Anionic surfactants useful in the present invention include, but are not limited to, soaps including alkali soaps, such as sodium, potassium and ammonium salts of aliphatic carboxylic acids, usually fatty acids, such as sodium stearate. Additional anionic surfactants include organic amine soaps such as organic amine salts of aliphatic carboxylic acids, usually fatty acids, such as triethanolamine stearate. Another class of useful soaps is the metallic soaps, salts of polyvalent metals and aliphatic carboxylic acids, usually fatty acids, such as aluminum stearate.
  • sulfated fatty acid alcohols such as sodium lauryl sulfate, sulfated oils such as the sulfuric ester of ricinoleic acid disodium salt, and sulfonated compounds such as alkyl sulfonates including sodium cetane sulfonate, amide sulfonates such as sodium N-methyl-N-oleyl laurate, sulfonated dibasic acid esters such as sodium dioctyl sulfosuccinate, alkyl aryl sulfonates such as sodium dodecylbenzene sulfonate, alkyl naphthalene sulfonates such a sodium isopropyl naphthalene sulfonate, petroleum sulfonate such as aryl naphthalene with alkyl substitutes.
  • anionic surfactants are useful in the present
  • Cationic surfactants useful in the present invention include, but are not limited to, amine salts such as octadecyl ammonium chloride and quaternary ammonium compounds such as benzalkonium chloride.
  • amine salts such as octadecyl ammonium chloride and quaternary ammonium compounds such as benzalkonium chloride.
  • quaternary ammonium compounds such as benzalkonium chloride.
  • cationic surfactants are useful in the present invention.
  • Additional surfactants useful in the present invention include sodium methylcocoyl taurate, sodium methyl oleoyl taurate, sodium lauryl sulfate, triethanolamine lauryl sulfate and betaines.
  • Fatty acid salts are also useful, and include, but are not limited to, organic salts such as ammonium and alkyl-ammonium salts, as well as inorganic salts such as sodium, potassium, magnesium and calcium salts.
  • organic salts such as ammonium and alkyl-ammonium salts
  • inorganic salts such as sodium, potassium, magnesium and calcium salts.
  • the surfactant of the foamable composition of the present invention can be a single surfactant or a mixture of several different surfactants.
  • the surfactant of the foamable composition of the present invention can be present in any suitable stabilizing amount. In one embodiment, the surfactant is present in an amount up to about 50% by weight, based on the total weight of the composition. In other embodiments, the surfactant is present in an amount of approximately 0.1% to about 10% by weight. One of skill in the art will appreciate that other amounts of surfactant are useful in the present invention.
  • Foamable compositions of the present invention comprise water in an amount up to 90% w/w, based on the total weight of the foamable composition. Some foamable compositions comprise water in an amount from about 45 % to about 90 % w/w, based on the total weight of the foamable composition. One of skill in the art will appreciate that foamable compositions having other amounts of water are useful in the present invention.
  • Emollients useful in the foamable compositions of the present invention are substances that soften and soothe the skin.
  • the foamable composition of the present invention can include an occlusive agent.
  • the occlusive agent of the foamable compositions of the present invention can be any excipient or combination thereof that provides an occlusive layer or hydration barrier to the skin.
  • An occlusive layer or hydration barrier is a layer or barrier sufficient to result in reduction in trans epidermal water loss, which results in skin hydration.
  • the occlusive agent in the foamable compositions of the present invention is selected from the group consisting of a mineral oil, grease, petrolatum, an animal fat, a vegetable fat, a water insoluble polymer, a fatty alcohol, and mixtures thereof.
  • the occlusive agent is white petrolatum.
  • the occlusive agent is a fatty alcohol, or combination of fatty alcohols, as described above.
  • the occlusive agent is a mixture of white petrolatum and a fatty alcohol or combination of fatty alcohols.
  • the occlusive agent is a mixture of white petrolatum and light mineral oil.
  • occlusive agents useful in the present invention include hydrophobic solvents such as mineral oil.
  • Mineral oil (Chemical Abstracts Service Registry number 8012-95-1) is a mixture of aliphatic, naphthalenic, and aromatic liquid hydrocarbons that are derived from petroleum. It is typically liquid; its viscosity is in the range of about 35 CST to about 100 CST (at 40° C), and its pour point (the lowest temperature at which an oil can be handled without excessive amounts of wax crystals forming) is below 0° C.
  • occlusive agents are liquid oils from vegetable, marine or animal sources.
  • the unsaturated oil may be selected from the group consisting of olive, com, soybean, canola, cottonseed, coconut, sesame, sunflower, borage seed, syzigium aromaticum, hempseed, herring, cod-liver, salmon, flaxseed, wheat germ and evening primrose oils and mixtures thereof, at any proportion.
  • oils suitable for use as the occlusive agent is liquid hydrophobic plant-derived oils, or essential oils, e.g. "therapeutic oils” containing active biologically occurring molecules that have a therapeutic effect when applied topically.
  • oils include rosehip oil, which contain retinoids and is known to reduce acne and post-acne scars, and tea tree oil, which possess antibacterial, antifungal and antiviral properties.
  • essential oils are oils of basil, camphor, cardamom, carrot, citronella, clary sage, clove, cypress, frankincense, ginger, grapefruit, hyssop, jasmine, lavender, lemon, mandarin, marjoram, myrrh, neroli, nutmeg, petitgrain, sage, tangerine, vanilla, verbena, as well as any other therapeutically beneficial oil, know in the art of herbal medication.
  • the occlusive agent comprises silicone oil.
  • Silicone oils are used in the foamable compositions due to their known skin protective and occlusive properties.
  • Suitable silicone oils for use in the invention include non-volatile silicones, such as polyalkyl siloxane, polyaryl siloxane, polyalkylaryl siloxanes and polyether siloxane copolymers, polydimethylsiloxanes (dimethicones) and poly(dimethylsiloxane)-(diphenyl- siloxane) copolymers.
  • cyclic or linear polydimethylsiloxanes containing from about 3 to about 9, preferably from about 4 to about 5, silicon atoms.
  • Volatile silicones such as cyclomethicones can also be used.
  • Water-soluble silicones, such as dimethicone copolyol are not included in the definition of silicone oils (as occlusive agents) according to the present invention.
  • Suitable emollients for use in the present invention include isostearic acid derivatives, isopropyl palmitate, lanolin oil, diisopropyl dimerate, diisopropyl adipate, dimethyl isosorbide, maleated soybean oil, octyl palmitate, isopropyl isostearate, cetyl lactate, cetyl ricinoleate, tocopheryl acetate, acetylated lanolin alcohol, cetyl acetate, phenyl trimethicone, glyceryl oleate, tocopheryl linoleate, wheat germ glycerides, arachidyl propionate, myristyl lactate, decyl oleate, propylene glycol ricinoleate, isopropyl lanolate, pentaerythrityl tetrastearate, neopentylglycol dicaprylate/
  • the composition comprises at least 2% (w/w foamable composition) silicone oil, alone or as part of the occlusive agent. Yet, in other embodiments, the composition comprises at least 5% (w/w) silicone oil alone or as part of the occlusive agent.
  • the occlusive agent can be present in an amount sufficient to permit the formation of an occlusive layer or hydration barrier on the skin of the patient.
  • the amount of occlusive agent present in the foamable composition of the present invention is from about 0.1% to approximately 55% by weight, based on the total weight of the foamable composition. In another embodiment, the amount of occlusive agent is present in an amount of from about 0.1% to about 25% by weight. In a further embodiment, the occlusive agent is present in an amount of from about 0.1% to about 10% by weight, based on the total weight of the foamable composition.
  • the amount of occlusive agent present in the foamable composition of the present invention is from about 0.1% to approximately 55% by weight, based on the total weight of the foamable composition. In another embodiment, the amount of occlusive agent is present in an amount of from about 0.1% to about 25% by weight. In a further embodiment, the occlusive agent is present in an amount of from about 0.1% to about 10% by weight, based on the total weight of the foamable composition.
  • Humectants useful in the foamable composition of the present invention include, but are not limited to, propylene glycol. When a humectant is present, it is present in an amount of from about 1% to about 20% by weight. In some embodiments, the humectant is present in an amount of from about 5% to about 15% by weight.
  • propylene glycol When a humectant is present, it is present in an amount of from about 1% to about 20% by weight. In some embodiments, the humectant is present in an amount of from about 5% to about 15% by weight.
  • humectants, and amounts are useful in the present invention.
  • the compositions contain a pH-adjusting agent, for example, an acid, a base, a buffering pair or a buffering agent.
  • the pH-adjusting agent is a buffering agent, for example, a buffering pair to stably maintain a desired pH.
  • the chosen buffering agent or buffering pair selected will depend on the active ingredients included in the composition.
  • the buffering agent or pH adjusting agent can be any inorganic or organic acid or base that maintains the pH at a desired point.
  • Buffering agents and/or pH adjusting agents useful in the present invention include, but are not limited to, sodium hydroxide, dibasic sodium phosphate anhydrous, and mixtures thereof.
  • the agent is sodium hydroxide.
  • the agent is dibasic sodium phosphate anhydrous. In a further embodiment, the agent is a mixture of sodium hydroxide and dibasic sodium phosphate anhydrous.
  • buffering agents or pH adjusting agents are useful in the present invention.
  • the pH of the foamable composition is from about pH 4.0 to about pH 9.0 (e.g., pH 4.0, 5.0, 6.0, 7.0, 8.0 or 9.0 and pH values in-between). In other embodiments, the pH is from about pH 7.0 to about pH 9.0.
  • pH 4.0 pH 4.0, 5.0, 6.0, 7.0, 8.0 or 9.0 and pH values in-between.
  • the pH is from about pH 7.0 to about pH 9.0.
  • pHs of the foamable compositions are useful in the present invention.
  • the desired pH is an acidic pH.
  • Exemplified buffering agents to maintain an acidic pH include, for example, citric acid/citrate, acetic acid/ acetate, BICINE, HEPES, Trizma.
  • the desired pH is a neutral pH.
  • Exemplified buffering agents to maintain a neutral pH include HEPES, TRIS, phosphoric acid/phosphate, Trizma.
  • the desired pH is a basic pH.
  • Exemplified buffering agents to maintain a basic pH include TRIS, Trizma, HEPES, carbonate/bicarbonate.
  • the buffering agent can also be an amino acid, for example, glycine, histidine, arginine, lysine, asparagine, aspartic acid, glutamine, glutamic acid.
  • an acid or a base for example, HCl, NaOH, KOH to arrive at the proper pH value.
  • the buffering agent or buffering pair can be included at a concentration of up to about 1%, usually up to about 0.3%, 0.5%, 0.7%, or in a range of about 0.1-1.0%, 0.3-0.8%.
  • the foamable compositions can contain about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.8, 0.9, 1.0% (w/w) of a buffering agent or a buffering pair.
  • buffering agent or pH adjusting agent When a buffering agent or pH adjusting agent is present, it is present in an amount of about 0.001% to about 1.0% by weight.
  • buffering agent or pH adjusting agent One of skill in the art will appreciate that other amounts of buffering agent or pH adjusting agent are useful in the present invention.
  • the foamable compositions of the present invention can also comprise additional adjuvants, such as a viscosity reducer, a complexing agent, a gelling agent, an antioxidant, a thickener, a preservative, a corrosion inhibitor, a penetration enhancer, colors and fragrances.
  • Viscosity reducers useful in the foamable composition of the present invention include, but are not limited to, isopropyl myristate, light mineral oil and cyclomethicone and mixtures thereof.
  • the foamable composition of the present invention comprises a mixture of isopropyl myristate, light mineral oil and cyclomethicone as a viscosity reducer. When a viscosity reducer is present, it is present in an amount of about 1% to about 20% by weight.
  • a viscosity reducer is present in an amount of about 1% to about 20% by weight.
  • Complexing agents useful in the foamable composition of the present invention include, but are not limited to, edetate disodium dehydrate. When a complexing agent is present, it is present in an amount of from about 0.001% to about 1%. One of skill in the art will appreciate that other complexing agents, and amounts, are useful in the present invention.
  • Gelling agents useful in the foamable composition of the present invention include, but are not limited to, amphiphilic copolymers.
  • Amphiphilic copolymers include polymers having hydrophobic groups and hydrophilic groups or regions. These materials are referred to alternatively as "polymeric surfactants" because the hydrophilic and hydrophobic regions of the polymers serve to interact with and stabilize hydrophilic and lipophilic components, respectively, of a composition.
  • the copolymer may be a random copolymer, a block copolymer or a graft copolymer.
  • Exemplary amphiphilic copolymers include di-, tri- or multi-block copolymer or graft copolymer of a biodegradable polymer.
  • the polymeric surfactant gelling agents may be an acrylate cross polymer.
  • suitable polymeric surfactants include cross linked copolymers of acrylic acid and a hydrophobic comonomer, such as Pemulen TR-I and Pemulen TR-2, ETD 2020 and Carbopol 1382 (all, Acrylates/ClO-30 alkyl acrylate crosspolymer), Natrosol CS Plus 330 and 430 and Polysurf 67 (all, cetyl hydroxyethyl cellulose), Aculyn 22 (acrylates/steareth-20 methacrylate copolymer), Aculyn 25 (acrylates/laureth-25 methacrylate copolymer), Aculyn 28 (acrylates/beheneth-25 methacrylate copolymer), Aculyn 46 (PEG-150/stearyl alcohol/SMDI copolymer), Stabylen 30 (acrylates/vinyl isodecanoate), Structure 2001 (acrylates/steare
  • amphiphilic copolymers include silicone polymers such as amphiphilic silicone polyols or copolyol, for example cetyl dimethicone copolyol and dimethicone copolyol PPG-3 oleyl ether, acetylated starch derivatives, amphiphilic modified starches, and amphiphilic block copolymers of ethylene oxide and propylene oxide (also known as "poloxamer").
  • silicone polymers such as amphiphilic silicone polyols or copolyol, for example cetyl dimethicone copolyol and dimethicone copolyol PPG-3 oleyl ether, acetylated starch derivatives, amphiphilic modified starches, and amphiphilic block copolymers of ethylene oxide and propylene oxide (also known as "poloxamer").
  • exemplary gelling agents include locust bean gum, sodium alginate, sodium caseinate, egg albumin, gelatin agar, carrageenin gum sodium alginate, xanthan gum, quince seed extract, tragacanth gum, starch, chemically modified starches and the like, semisynthetic polymeric materials such as cellulose ethers (e.g.
  • the gelling agent can be present in the foamable composition in an amount of about 0.1 to 5.0 wt % by weight.
  • the gelling agent included in the foamable composition can be less than 1 wt % by weight of the foamable composition.
  • An antioxidant useful in the present invention is one that retards oxidation and subsequent deterioration of the pharmaceutically active agent.
  • antioxidants useful in the compositions of the present invention include, but are not limited to, beta- carotene, selenium, coenzyme QlO (ubiquinone), lutein, tocotrienols, soy isoflavones, S- adenosylmethionine, glutathione, taurine, N-acetylcysteine, Vitamin E, Vitamin C, alpha- lipoic acid, 1-carnitine, phenoxyethanol, butylated hydroxytoluene and sodium benzoate.
  • Antioxidants are also known as preservatives.
  • a penetration enhancer or permeation enhancer is useful in the foamable compositions of the present invention.
  • a penetration enhancer or permeation enhancer is an agent used to increase the permeability of the skin to a pharmaceutically active agent to increase the rate at which the drug diffuses through the skin and enters the tissues and bloodstream.
  • a chemical skin penetration enhancer increases skin permeability by reversibly altering the physiochemical nature of the stratum comeum to reduce its diffusional resistance.
  • Examples of penetration enhancers include: polyols, such as propyleneglycol, hexylene glycol, diethylene glycol, propylene glycol n- alkanols, terpenes, di-terpenes, tri-terpenes, terpen-ols, limonen, terpene-ol, 1 -menthol, dioxolane, ethylene glycol, other glycols, and glycerol; sulfoxides, such as dimethylsulfoxide (DMSO), dimethylformamide, methyl dodecyl sulfoxide, dimethylacetamide; monooleate of ethoxylated glycerides (with 8 to 10 ethylene oxide units); Azone (1-dodecylazacycloheptan- 2-one), 2-(n-nonyl)-l, 3-dioxolane; esters, such as isopropyl myristate/palmitate
  • Cyclodextrins are structurally related cyclic oligomaltoses which form a new group of pharmaceutical excipients. These are torus-shaped molecules with a hydrophilic outer surface and a lipophilic central cavity. Cyclodextrins are capable of forming water- soluble inclusion complexes with a wide variety of lipophilic water-insoluble drugs by taking up a whole drug molecule, or some part of it, into the cavity.
  • the cyclodextrin molecules are relatively large (molecular weight ranging from almost 1000 to over 1500), with a hydrated outer surface, and under normal conditions, cyclodextrin molecules will only permeate the skin barrier with considerable difficulty. It is generally believed that the cyclodextrin molecules act as true carriers by keeping lipophilic drug molecules in solution and deliver them to the skin surface where they partition from the cyclodextrin cavity into the skin.
  • the compositions of the present invention include a thickener.
  • a thickener increases viscosity without substantially modifying other properties of a composition to which it is added.
  • Thickeners provide body, increase stability, and improve suspending action.
  • Thickeners useful in the compositions of the instant invention include, but are not limited to, agar, alginin, arrowroot, collagen, cornstarch, fecula, gelatin, guar gum, katakuri, locust bean gum, pectin, roux, tapioca, and xanthan gum.
  • thinners of the present invention include, but are not limited to, agar, alginin, arrowroot, collagen, cornstarch, fecula, gelatin, guar gum, katakuri, locust bean gum, pectin, roux, tapioca, and xanthan gum.
  • compositions can further include a corticosteroid such as those set forth in U.S. Patent No. 6,126,920, which is incorporated herein by reference.
  • Suitable corticosteroids include, for example, alclometasone dipropionate, fluclorolone acetonide, amcinonide, fluocinolone acetonide, beclamethasone dipropionate, fluocinonide, betamethasone benzoate, fluocortin butyl, betamethasone dipropionate, fluocortolone preparations, betamethasone valerate, fluprednidene acetate, budesonide, flurandrenolone, clobetasol propionate, halcinonide, clobetasone butyrate, hydrocortisone, desonide, hydrocortisone acetate, desoxymethasone, hydrocortisone butyrate, diflorasone diacetate, methylprednisolone acetate, diflucortolone valerate, mometasone furoate, flumethasone pivalate, triamcinolone ace
  • the foamable compositions of the present invention can also comprise an effective amount of an aerosol propellant.
  • the aerosol propellant can be any suitable gas or mixture thereof, such as a hydrocarbon, a chlorofluorocarbon, dimethyl ether, hydro fluorocarbons and a mixture thereof.
  • Additional foamable compositions can comprise an aerosol propellant such as nitrogen or air.
  • the aerosol propellant is a mixture of hydrocarbons.
  • the aerosol propellant is a mixture of propane, rt-butane and isobutane. When such a mixture of hydrocarbon gasses is used as the aerosol propellant, the propane can be present in an amount of from about 10% to about 90% of the propellant mixture.
  • the propane can be present in an amount of from about 40% to about 70%.
  • the n-butane used in such a mixture can be present in an amount from about 5% to about 50%.
  • the «-butane can be present in an amount from about 20% to about 40%.
  • the isobutane used in such a mixture can be present in an amount from about 1 % to about 30%. In some embodiments, the isobutane can be present in an amount from about 10% to about 20%.
  • the aerosol propellant can be present in the foamable composition in an amount of from approximately 2.5% to 20% by weight of the foamable composition, or 5% to 15% by weight. In some embodiments, the aerosol propellant is present in an amount from about 5% to 10% by weight, such as 5%, 6%, 7%, 8%, 9% or 10% by weight.
  • the propellant may be introduced into the foamable composition at the time of filling utilizing a pressurized container such as a standard aerosol dispenser.
  • a pressurized container such as a standard aerosol dispenser.
  • the foamable composition is a foam.
  • the foam breaks easily with shear. More preferably, the foam is homogenous.
  • a preferred composition of the present invention includes imiquimod as the immune response modifier compound in an amount of about 0.001% to 10% by weight, a Cis fatty acid as the organic solvent in an amount of from about 10% to about 50% by weight.
  • a base in an amount from about 0.01% to about 30% by weight, and water in an amount of about 45% to about 90% by weight.
  • foamable compositions of the present invention are comprised of different components or in different amounts.
  • the present invention includes a method for treating a dermato logical disorder in a mammal, the method comprising the step of administering a foamable composition of the invention to treat the dermatological disorder.
  • Dermatological disorders that are treatable by the methods of the present invention include, but are not limited to, dermatological conditions linked to disorders of keratinization involving differentiation and proliferation, in particular, acne vulgaris, comedonic or polymorphic acne, nodulocystic acne, acne conglobata, senile acne and secondary acnes such as solar, drug or occupational acne; for other types of keratinization disorders especially ichthyoses, ichthyosiform conditions, Darier's disease, palmoplantar keratoderma, leukoplakia and luecoplakiform conditions or lichen and lichen planus; dermatological disorders having an inflammatory or immunoallergic component, in particular, all forms of psoriases, either cutaneous, mucosal or ungual, and psoriatic rheumatism, and cutaneous atopy such as eczema or respiratory atopy, dry skin, inflammation of the skin, solar erythema, skin allergies or other skin
  • disorders treatable by the methods of the present invention include precancerous lesions such as actinic keratosis, melanoma and nonmelanoma skin cancers (such as basal cell carcinoma), and warts (such as external genital warts).
  • the present invention contemplates the treatment of skin disorders of humans and animals.
  • the dermatological disorder treated by the methods of the present invention is psoriasis or atopic dermatitis.
  • the dermatological disorder treated is actinic keratosis, basal cell carcinoma or external genital warts.
  • One of skill in the art will appreciate that other dermatological disorders are useful in the present invention.
  • foamable compositions useful in the methods of the present invention are described above.
  • the foamable composition is administered topically.
  • the physical stability of aerosol foam is influenced by the cohesive forces that exist between the aerosol base (i.e. the foamable composition) and the aerosol propellant (i.e. the foaming agent).
  • the rheological characterization of a foam structure is relevant in determining whether foam will persist or break easily with shear. For example, in order for foam to persist the foam structure requires sufficient viscosity at near zero shear rates to exhibit this behavior.
  • the yield stress required to deform the foam structure provides an indication of the foam's ability to maintain the physical structure during the application of shear forces. Also, subjecting foam to constant shear will provide a measure of the foam's ability to retain its structure.
  • Step 1 the shear rate is increased from 10 to 100 (s 1 ) over a 60 second period
  • Step 2 the shear rate of 100 (s '1 ) is maintained for 10 seconds
  • Step 3 the shear rate is decreased from 100 to 10 (s "1 ) over a 60 second period.
  • the Yield Stress is calculated in Step 1 , the Average Viscosity is determined during Step 2 and the Change in Viscosity is determined by the difference between the Initial Viscosity (Start of Step 1) and the Final Viscosity (End of Step 3).
  • Foam is dispensed from each sample of partially-neutralized fatty acid foam.
  • an active ingredient e.g. Imiquimod
  • the active ingredient e.g. Imiquimod
  • the active ingredient can contribute to the neutralization of the fatty acid solvent.
  • Partially-neutralized fatty acid foams that contain an active ingredient can persist when neutralized beyond approximately 35%, whereas those neutralized below approximately 35% break easily with shear.
  • an active ingredient e.g. Imiquimod
  • Foam is dispensed from each sample of partially-neutralized fatty acid foam.
  • Foam is dispensed from each sample of partially-neutralized fatty acid foam.
  • Foam is dispensed from each sample of partially-neutralized fatty acid foam.
  • the active ingredient comprises the sole neutralizing agent (i.e. acts as the base), foam was dispensed from each sample of partially-neutralized fatty acid foam.
  • the Foam Stability Value increases as the proportion of solid, lipophilic materials are added (e.g. Cetyl alcohol, Stearic acid, etc).
  • the active ingredient comprises the sole neutralizing agent (i.e. acts as the base), foam was dispensed from each sample of partially-neutralized fatty acid foam.
  • the Foam Stability Value increases as the proportion of solid, lipophilic materials are added (e.g. Stearic acid).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition pharmaceutique qui contient de l'eau et un solvant organique, ledit solvant organique comprenant de l'acide gras. La composition de l'invention, qui peut également comprendre un agent pharmaceutiquement actif, est également utile pour le traitement d'un trouble dermatologique effectué chez un mammifère par administration topique.
PCT/US2007/015826 2006-07-14 2007-07-12 Mousse pharmaceutique à base d'acide gras WO2008008397A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA2659095A CA2659095C (fr) 2006-07-14 2007-07-12 Mousse pharmaceutique a base d'acide gras
ES07810355T ES2393761T3 (es) 2006-07-14 2007-07-12 Espuma farmacéutica de ácido graso
PL07810355T PL2046121T3 (pl) 2006-07-14 2007-07-12 Farmaceutyczna pianka oparta na kwasie tłuszczowym
EP07810355A EP2046121B1 (fr) 2006-07-14 2007-07-12 Mousse pharmaceutique a base d'acide gras
MX2009000507A MX2009000507A (es) 2006-07-14 2007-07-12 Espuma farmaceutica de acidos grasos.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83094906P 2006-07-14 2006-07-14
US60/830,949 2006-07-14

Publications (3)

Publication Number Publication Date
WO2008008397A2 true WO2008008397A2 (fr) 2008-01-17
WO2008008397A3 WO2008008397A3 (fr) 2008-10-30
WO2008008397A8 WO2008008397A8 (fr) 2009-02-26

Family

ID=38923869

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/015826 WO2008008397A2 (fr) 2006-07-14 2007-07-12 Mousse pharmaceutique à base d'acide gras

Country Status (9)

Country Link
US (2) US9023863B2 (fr)
EP (1) EP2046121B1 (fr)
AR (1) AR062059A1 (fr)
CA (1) CA2659095C (fr)
ES (1) ES2393761T3 (fr)
MX (1) MX2009000507A (fr)
PL (1) PL2046121T3 (fr)
TW (1) TW200819146A (fr)
WO (1) WO2008008397A2 (fr)

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009101199A2 (fr) * 2008-02-15 2009-08-20 Bodo Melnik Traitement de l'acné vulgaire, de la rosacée et du rhinophyme
WO2010115164A1 (fr) * 2009-04-03 2010-10-07 Medicis Pharmaceutical Corporation Compositions topiques
WO2011038446A1 (fr) * 2009-09-30 2011-04-07 Stiefel Research Australia Pty Ltd Mousse cosmétique
EP2340043A1 (fr) * 2008-10-31 2011-07-06 Moberg Derma AB Composition topique comprenant une combinaison d au moins deux agents de pénétration
WO2012085481A1 (fr) * 2010-12-23 2012-06-28 Galderma Research & Development Mousses dermatologiques obtenues à partir d'un gel ou d'une suspension contenant de l'adapalène
US8343945B2 (en) 2007-12-07 2013-01-01 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US8435498B2 (en) 2002-10-25 2013-05-07 Foamix Ltd. Penetrating pharmaceutical foam
US8486375B2 (en) 2003-04-28 2013-07-16 Foamix Ltd. Foamable compositions
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US8518378B2 (en) 2003-08-04 2013-08-27 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
US8618081B2 (en) 2009-10-02 2013-12-31 Foamix Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US8709385B2 (en) 2008-01-14 2014-04-29 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US8722021B2 (en) 2002-10-25 2014-05-13 Foamix Ltd. Foamable carriers
US8795635B2 (en) 2006-11-14 2014-08-05 Foamix Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US9072667B2 (en) 2009-07-29 2015-07-07 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9101662B2 (en) 2003-08-04 2015-08-11 Foamix Pharmaceuticals Ltd. Compositions with modulating agents
US9167813B2 (en) 2009-07-29 2015-10-27 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9636405B2 (en) 2003-08-04 2017-05-02 Foamix Pharmaceuticals Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9662298B2 (en) 2007-08-07 2017-05-30 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
EP3283051A4 (fr) * 2015-04-16 2019-01-02 Kate Somerville Skincare, LLC Compositions auto-moussantes et procédés
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
US10702466B2 (en) 2006-12-21 2020-07-07 Galderma Research & Development Emulsions comprising at least one retinoid and benzoyl peroxide
US10925814B2 (en) 2006-12-21 2021-02-23 Galderma Research & Development Cream gels comprising at least one retinoid and benzoyl peroxide
US12138311B2 (en) 2020-02-28 2024-11-12 Journey Medical Corporation Topical tetracycline compositions

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263580B2 (en) 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
US20050271596A1 (en) * 2002-10-25 2005-12-08 Foamix Ltd. Vasoactive kit and composition and uses thereof
US8119109B2 (en) * 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
AU2004266502B2 (en) * 2002-10-25 2010-09-23 Foamix Pharmaceuticals Ltd. Penetrating pharmaceutical foam
US20050205086A1 (en) * 2002-10-25 2005-09-22 Foamix Ltd. Retinoid immunomodulating kit and composition and uses thereof
US20070292359A1 (en) * 2002-10-25 2007-12-20 Foamix Ltd. Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof
US20060018937A1 (en) * 2002-10-25 2006-01-26 Foamix Ltd. Steroid kit and foamable composition and uses thereof
US20050186142A1 (en) * 2002-10-25 2005-08-25 Foamix Ltd. Kit and composition of imidazole with enhanced bioavailability
US20080206161A1 (en) * 2002-10-25 2008-08-28 Dov Tamarkin Quiescent foamable compositions, steroids, kits and uses thereof
US20060193789A1 (en) * 2002-10-25 2006-08-31 Foamix Ltd. Film forming foamable composition
US8486376B2 (en) * 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US20070292355A1 (en) * 2002-10-25 2007-12-20 Foamix Ltd. Anti-infection augmentation foamable compositions and kit and uses thereof
US8486374B2 (en) * 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
MXPA06001381A (es) * 2003-08-04 2006-05-19 Foamix Ltd Vehiculo de espuma que contiene un gelificante copolimerico anfifilico.
US20080069779A1 (en) * 2003-08-04 2008-03-20 Foamix Ltd. Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof
JP2005310310A (ja) * 2004-04-23 2005-11-04 Sanyo Electric Co Ltd トラッキングバランス調整装置
ES2407407T3 (es) 2005-06-01 2013-06-12 Glaxosmithkline Intellectual Property Development Limited Formulación de vitamina
CA2658031C (fr) * 2006-07-18 2015-06-02 Graceway Pharmaceuticals, Llc Formulations de mousse a modificateur d'immuno-reaction comportant de l'imiquimod et un acide gras
US20080166303A1 (en) * 2006-09-08 2008-07-10 Dov Tamarkin Colored or colorable foamable composition and foam
US20080206155A1 (en) * 2006-11-14 2008-08-28 Foamix Ltd. Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses
US20080292560A1 (en) * 2007-01-12 2008-11-27 Dov Tamarkin Silicone in glycol pharmaceutical and cosmetic compositions with accommodating agent
US8580860B2 (en) * 2007-02-23 2013-11-12 Gojo Industries, Inc. Foamable alcoholic composition
US20090130029A1 (en) * 2007-11-21 2009-05-21 Foamix Ltd. Glycerol ethers vehicle and pharmaceutical compositions thereof
US20090136430A1 (en) * 2007-11-27 2009-05-28 Dugger Harry A Antihistamine/Corticosteroid preparations for the treatment of atopic dermatitis
US8652443B2 (en) * 2008-02-14 2014-02-18 Precision Dermatology, Inc. Foamable microemulsion compositions for topical administration
US20100160368A1 (en) * 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
WO2010045435A2 (fr) * 2008-10-15 2010-04-22 Quinnova Pharmaceuticals, Inc. Composition d’acide salicylique
FR2938436B1 (fr) * 2008-11-18 2011-08-26 Natura Cosmeticos Sa Composition cosmetique pour le nettoyage de la peau
SI2378876T1 (sl) 2008-12-19 2019-05-31 Medicis Pharmaceutical Corporation Formulacije z nižjo dozirno jakostjo imikvimoda in kratki odmerni režimi za zdravljenje aktinične keratoze
US20120238535A1 (en) * 2009-02-23 2012-09-20 Smith Jan G Topical formulation of low level clobetasol propionate for treating disorders of the skin and mucous membranes
ES2653313T3 (es) * 2009-07-13 2018-02-06 Medicis Pharmaceutical Corporation Formulaciones de imiquimod con concentración de dosificación menor y regímenes de dosificación cortos para el tratamiento de verrugas genitales y perianales
US8174881B2 (en) 2009-11-24 2012-05-08 Micron Technology, Inc. Techniques for reducing disturbance in a semiconductor device
US8859259B2 (en) * 2010-02-14 2014-10-14 Ls9, Inc. Surfactant and cleaning compositions comprising microbially produced branched fatty alcohols
US10543172B2 (en) * 2010-10-26 2020-01-28 Paragon Nordic Ab Econazole composition and methods of treatment therewith
EP3242869B1 (fr) * 2015-01-06 2021-10-27 Cellixbio Private Limited Compositions et méthodes pour le traitement d'une inflammation et de la douleur
KR102164102B1 (ko) * 2015-03-05 2020-10-12 (주)아모레퍼시픽 화산석 송이를 포함하는 무스제형 화장료 조성물
SG11201805109YA (en) * 2015-12-15 2018-07-30 Therapeutics Inc Halobetasol foam composition and method of use thereof
MY188053A (en) 2015-12-15 2021-11-15 Therapeutics Inc Corticosteroid containing foam compositions and method of manufacture thereof
US20190008969A1 (en) * 2017-07-06 2019-01-10 Tioga Research, Inc. Compositions for drug delivery
JP2021524505A (ja) * 2018-05-19 2021-09-13 ゲイリー ビンヤミン， 発泡体製剤および身体への送達法
US10889752B2 (en) 2019-02-05 2021-01-12 Saudi Arabian Oil Company Foaming mixtures and methods of use thereof
US11549066B1 (en) 2021-08-10 2023-01-10 Cameron International Corporation Citrate polyester additives for crude oil, mixtures of said additives and crude oil, and methods for producing said mixtures
CN116642990A (zh) * 2023-03-14 2023-08-25 华南农业大学 一种鉴别余甘子挥发性风味物质的方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE358308B (fr) * 1971-11-26 1973-07-30 Pharmacia Ab
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4822605A (en) 1986-02-18 1989-04-18 Exovir, Inc. Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like
PH25150A (en) * 1986-06-05 1991-03-13 Ciba Geigy Ag Novel pharmaceutical preparation for topical application
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5736553A (en) * 1988-12-15 1998-04-07 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo 4,5-C!quinolin-4-amine
IL92537A (en) 1988-12-15 1994-04-12 Riker Laboratories Inc Topical preparations and dermal systems containing 1-isobutyl-H1-imidazo [C-4,5] quinoline-4-amine
US5589515A (en) * 1991-09-27 1996-12-31 Nof Corporation Cosmetic composition and an emulsion composition
SE520811C2 (sv) * 1997-01-17 2003-08-26 Ponsus Ab Hudskyddspreparat innehållande lipofila och hydrofila komponenter, förfarande för framställning och användning därav
US6423323B2 (en) * 1997-08-18 2002-07-23 Stephanie Neubourg Foam skin cream, uses of the foam skin protection cream and a process for its preparation
AUPP583198A0 (en) * 1998-09-11 1998-10-01 Soltec Research Pty Ltd Mousse composition
US20020058674A1 (en) * 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
US6894060B2 (en) * 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
DE10155956A1 (de) * 2001-11-09 2003-05-22 Beiersdorf Ag Selbstschäumende, schaumförmige, nachschäumende oder schäumbare kosmetische oder dermatologische Zubereitungen
AU2004220469B2 (en) * 2001-11-29 2010-07-29 3M Innovative Properties Company Methods of improving skin quality
CN100473384C (zh) * 2001-11-29 2009-04-01 3M创新有限公司 包括免疫反应改性剂的药物制剂
ES2541132T3 (es) * 2002-02-22 2015-07-16 Meda Ab Método para reducir y tratar la inmunosupresión inducida por UV-B
WO2004037225A2 (fr) 2002-10-25 2004-05-06 Foamix Ltd. Mousse cosmetique et pharmaceutique
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US7186416B2 (en) 2003-05-28 2007-03-06 Stiefel Laboratories, Inc. Foamable pharmaceutical compositions and methods for treating a disorder
US20050020552A1 (en) * 2003-07-16 2005-01-27 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
GB0323908D0 (en) * 2003-10-11 2003-11-12 Nupharm Lab Ltd Pharmaceutical foam formulation
RS51476B (en) * 2003-12-30 2011-04-30 Gilead Sciences, Inc. PHOSPHONATES, MONOSPHOSPHONAMIDATES, BISPHOSPHONAMIDATES FOR THE TREATMENT OF VIRAL DISEASES
US20060105029A1 (en) * 2004-11-12 2006-05-18 Jie Zhang Instant patch for dermal drug delivery
US20070142255A1 (en) * 2005-12-16 2007-06-21 Conopco, Inc., D/B/A Unilever Skin benefit composition and a method for using the same
US7186146B1 (en) * 2006-02-09 2007-03-06 Pen Yen Chang Electric appliance/extension cord assembly with electromagnetic radiation-shielding function

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None
See also references of EP2046121A4

Cited By (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US9713643B2 (en) 2002-10-25 2017-07-25 Foamix Pharmaceuticals Ltd. Foamable carriers
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9492412B2 (en) 2002-10-25 2016-11-15 Foamix Pharmaceuticals Ltd. Penetrating pharmaceutical foam
US11033491B2 (en) 2002-10-25 2021-06-15 Vyne Therapeutics Inc. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US10821077B2 (en) 2002-10-25 2020-11-03 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US8435498B2 (en) 2002-10-25 2013-05-07 Foamix Ltd. Penetrating pharmaceutical foam
US8840869B2 (en) 2002-10-25 2014-09-23 Foamix Ltd. Body cavity foams
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US8741265B2 (en) 2002-10-25 2014-06-03 Foamix Ltd. Penetrating pharmaceutical foam
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US8722021B2 (en) 2002-10-25 2014-05-13 Foamix Ltd. Foamable carriers
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US10322085B2 (en) 2002-10-25 2019-06-18 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US8486375B2 (en) 2003-04-28 2013-07-16 Foamix Ltd. Foamable compositions
US8703105B2 (en) 2003-08-04 2014-04-22 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US9636405B2 (en) 2003-08-04 2017-05-02 Foamix Pharmaceuticals Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8518378B2 (en) 2003-08-04 2013-08-27 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US9050253B2 (en) 2003-08-04 2015-06-09 Foamix Pharmaceuticals Ltd. Oleaginous pharmaceutical and cosmetic foam
US9101662B2 (en) 2003-08-04 2015-08-11 Foamix Pharmaceuticals Ltd. Compositions with modulating agents
US8795635B2 (en) 2006-11-14 2014-08-05 Foamix Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US9682021B2 (en) 2006-11-14 2017-06-20 Foamix Pharmaceuticals Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US10702466B2 (en) 2006-12-21 2020-07-07 Galderma Research & Development Emulsions comprising at least one retinoid and benzoyl peroxide
US10925814B2 (en) 2006-12-21 2021-02-23 Galderma Research & Development Cream gels comprising at least one retinoid and benzoyl peroxide
US9662298B2 (en) 2007-08-07 2017-05-30 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US10369102B2 (en) 2007-08-07 2019-08-06 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US11103454B2 (en) 2007-08-07 2021-08-31 Vyne Therapeutics Inc. Wax foamable vehicle and pharmaceutical compositions thereof
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
US9549898B2 (en) 2007-12-07 2017-01-24 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US9161916B2 (en) 2007-12-07 2015-10-20 Foamix Pharmaceuticals Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US11433025B2 (en) 2007-12-07 2022-09-06 Vyne Therapeutics Inc. Oil foamable carriers and formulations
US9795564B2 (en) 2007-12-07 2017-10-24 Foamix Pharmaceuticals Ltd. Oil-based foamable carriers and formulations
US8343945B2 (en) 2007-12-07 2013-01-01 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US8900553B2 (en) 2007-12-07 2014-12-02 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US8709385B2 (en) 2008-01-14 2014-04-29 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
WO2009101199A2 (fr) * 2008-02-15 2009-08-20 Bodo Melnik Traitement de l'acné vulgaire, de la rosacée et du rhinophyme
WO2009101199A3 (fr) * 2008-02-15 2009-11-26 Bodo Melnik Traitement de l'acné vulgaire, de la rosacée et du rhinophyme
EP2340043A4 (fr) * 2008-10-31 2012-09-19 Moberg Derma Ab Composition topique comprenant une combinaison d au moins deux agents de pénétration
EP2340043A1 (fr) * 2008-10-31 2011-07-06 Moberg Derma AB Composition topique comprenant une combinaison d au moins deux agents de pénétration
WO2010115164A1 (fr) * 2009-04-03 2010-10-07 Medicis Pharmaceutical Corporation Compositions topiques
US10363216B2 (en) 2009-04-28 2019-07-30 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10588858B2 (en) 2009-04-28 2020-03-17 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10213384B2 (en) 2009-04-28 2019-02-26 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10350166B2 (en) 2009-07-29 2019-07-16 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9167813B2 (en) 2009-07-29 2015-10-27 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US11219631B2 (en) 2009-07-29 2022-01-11 Vyne Pharmaceuticals Inc. Foamable compositions, breakable foams and their uses
US10092588B2 (en) 2009-07-29 2018-10-09 Foamix Pharmaceuticals Ltd. Foamable compositions, breakable foams and their uses
US9572775B2 (en) 2009-07-29 2017-02-21 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9072667B2 (en) 2009-07-29 2015-07-07 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011038446A1 (fr) * 2009-09-30 2011-04-07 Stiefel Research Australia Pty Ltd Mousse cosmétique
EA021024B1 (ru) * 2009-09-30 2015-03-31 Стифел Рисерч Оустрэйлиа Пти Лтд. Косметическая пена
US10463742B2 (en) 2009-10-02 2019-11-05 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US8871184B2 (en) 2009-10-02 2014-10-28 Foamix Ltd. Topical tetracycline compositions
US10213512B2 (en) 2009-10-02 2019-02-26 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10238746B2 (en) 2009-10-02 2019-03-26 Foamix Pharmaceuticals Ltd Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10265404B2 (en) 2009-10-02 2019-04-23 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US9675700B2 (en) 2009-10-02 2017-06-13 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10322186B2 (en) 2009-10-02 2019-06-18 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10137200B2 (en) 2009-10-02 2018-11-27 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10086080B2 (en) 2009-10-02 2018-10-02 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US8992896B2 (en) 2009-10-02 2015-03-31 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10029013B2 (en) 2009-10-02 2018-07-24 Foamix Pharmaceuticals Ltd. Surfactant-free, water-free formable composition and breakable foams and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US10517882B2 (en) 2009-10-02 2019-12-31 Foamix Pharmaceuticals Ltd. Method for healing of an infected acne lesion without scarring
US8945516B2 (en) 2009-10-02 2015-02-03 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10610599B2 (en) 2009-10-02 2020-04-07 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10967063B2 (en) 2009-10-02 2021-04-06 Vyne Therapeutics Inc. Surfactant-free, water-free formable composition and breakable foams and their uses
US10821187B2 (en) 2009-10-02 2020-11-03 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US8865139B1 (en) 2009-10-02 2014-10-21 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10835613B2 (en) 2009-10-02 2020-11-17 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US10946101B2 (en) 2009-10-02 2021-03-16 Vyne Therapeutics Inc. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US8618081B2 (en) 2009-10-02 2013-12-31 Foamix Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US9271930B2 (en) 2010-12-23 2016-03-01 Galderma Research And Development Dermatological foams obtained from a gel or suspension containing adapalene
FR2969492A1 (fr) * 2010-12-23 2012-06-29 Galderma Res & Dev Mousses dermatologiques obtenues a partir d'un gel ou d'une suspension contenant de l'adapalene
WO2012085481A1 (fr) * 2010-12-23 2012-06-28 Galderma Research & Development Mousses dermatologiques obtenues à partir d'un gel ou d'une suspension contenant de l'adapalène
EP3283051A4 (fr) * 2015-04-16 2019-01-02 Kate Somerville Skincare, LLC Compositions auto-moussantes et procédés
US10849847B2 (en) 2016-09-08 2020-12-01 Foamix Pharamaceuticals Ltd. Compositions and methods for treating rosacea and acne
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
US11324691B2 (en) 2016-09-08 2022-05-10 Journey Medical Corporation Compositions and methods for treating rosacea and acne
US12138311B2 (en) 2020-02-28 2024-11-12 Journey Medical Corporation Topical tetracycline compositions

Also Published As

Publication number Publication date
EP2046121A2 (fr) 2009-04-15
WO2008008397A3 (fr) 2008-10-30
EP2046121B1 (fr) 2012-08-22
US20150209280A1 (en) 2015-07-30
AR062059A1 (es) 2008-10-15
WO2008008397A8 (fr) 2009-02-26
US20080015271A1 (en) 2008-01-17
TW200819146A (en) 2008-05-01
MX2009000507A (es) 2009-06-12
US9827195B2 (en) 2017-11-28
CA2659095A1 (fr) 2008-01-17
US9023863B2 (en) 2015-05-05
EP2046121A4 (fr) 2010-10-20
PL2046121T3 (pl) 2013-01-31
ES2393761T3 (es) 2012-12-27
CA2659095C (fr) 2015-04-28

Similar Documents

Publication Publication Date Title
US9827195B2 (en) Fatty acid pharmaceutical foam
US11033491B2 (en) Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US11103454B2 (en) Wax foamable vehicle and pharmaceutical compositions thereof
US10322085B2 (en) Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
JP6182191B2 (ja) 局所用フォーム組成物
US8709385B2 (en) Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
EP2494959B1 (fr) Véhicule moussant à base d'acide dicarboxylique et ses compositions pharmaceutiques
JP2006505583A (ja) 化粧剤および医薬用フォーム
ZA200507018B (en) Oleaginous pharmaceutical and cosmetic foam

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07810355

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2659095

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/000507

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007810355

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU